Global Leading Market Research Publisher QYResearch announces the release of its latest report “Drug-containing Fat Emulsion – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Drug-containing Fat Emulsion market, including market size, share, demand, industry development status, and forecasts for the next few years.
Why are pharmaceutical companies, drug delivery researchers, and clinicians adopting drug-containing fat emulsions for insoluble and poorly bioavailable drugs? Many promising drug candidates face three critical formulation challenges: poor water solubility (up to 40–60% of new chemical entities are poorly soluble, limiting bioavailability), stability issues (drugs degrade during storage or in vivo), and adverse reactions (intravenous administration of certain drugs causes phlebitis, pain, or organ toxicity). Drug-containing fat emulsion is an oil-in-water (O/W) emulsion made with vegetable oil (primarily fatty acid triglycerides) as the oil phase, supplemented with phospholipid emulsifiers, isotonic agents, and water for injection. Fat emulsion was first used for parenteral nutrition supplementation. Drug-containing fat emulsion solves problems of drug insolubility and drug stability, ensures drug stability during storage, and reduces adverse reactions in patients. Fat emulsions offer advantages: non-toxicity, high drug loading, ability to withstand heat press sterilization, and suitability for large-scale industrial production. As a drug carrier, drug-containing fat emulsion has broad application prospects. Insoluble drugs are wrapped in the oil core (100–300 nm particle size), with some drugs distributed in the phospholipid layer. These emulsions are widely used in anesthesia, analgesia, cardiovascular therapy, and anti-cancer applications – including propofol medium- and long-chain fat emulsion injection, clevidipine butyrate fat emulsion injection, and drug-containing fat emulsions for cancer therapy.
The global market for Drug-containing Fat Emulsion was estimated to be worth US$ 2,300 million in 2024 and is forecast to reach a readjusted size of US$ 5,085 million by 2031, growing at a CAGR of 12.0% during the forecast period 2025-2031. In 2024, global production of drug-containing fat emulsion reached 326.70 million tons, with the Chinese market size reaching US$ 1,303 million (approximately 57% of global market), and an average selling price of US$ 7.04 per gram.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4916425/drug-containing-fat-emulsion
Product Definition: What Is Drug-containing Fat Emulsion?
Drug-containing fat emulsion is a colloidal drug delivery system where drug molecules are incorporated into oil-in-water (O/W) emulsion droplets (100–300 nm diameter). The emulsion consists of: (a) oil phase – vegetable oils (soybean oil, medium-chain triglycerides (MCT), olive oil, fish oil) serving as drug carrier for lipophilic drugs; (b) aqueous phase – water for injection; (c) emulsifier – phospholipids (egg lecithin, soy lecithin) stabilizing the oil-water interface; (d) drug – incorporated in oil core or phospholipid layer depending on lipophilicity; (e) tonicity agent – glycerin to achieve isotonicity (280–310 mOsm/L). Drug incorporation mechanisms: (i) oil-soluble drugs – dissolved in oil phase (propofol, clevidipine, diazepam); (ii) amphiphilic drugs – intercalated into phospholipid layer; (iii) water-soluble drugs – encapsulated in aqueous phase (less common). Key advantages over conventional formulations: (a) improved solubility – poorly water-soluble drugs dissolved in oil phase, achieving therapeutic concentrations; (b) reduced toxicity – drug encapsulation reduces direct contact with vascular endothelium, decreasing phlebitis, pain, and hemolysis; (c) sustained release – drug released gradually from oil droplets; (d) sterilization – emulsions withstand autoclave (121°C, 15–20 minutes) without degradation; (e) scalable manufacturing – high-pressure homogenization (500–1,500 bar, 5–10 cycles) produces uniform droplet size distribution. Key applications: anesthesia – propofol (Diprivan), etomidate; analgesia – flurbiprofen axetil, ketoprofen; cardiovascular – clevidipine (Cleviprex – ultra-short-acting calcium channel blocker for hypertension), alprostadil (prostaglandin E1 for peripheral arterial disease); anti-cancer – paclitaxel, docetaxel, curcumin; anti-inflammatory – dexamethasone; anti-infective – amphotericin B (less nephrotoxic than conventional formulation).
Market Segmentation: Administration Route and Patient Population
By Administration Route:
- Fat Emulsion Intravenous Injection – Largest segment (70–75% of market value). Propofol (anesthesia), clevidipine (hypertension), flurbiprofen (analgesia), alprostadil (peripheral arterial disease), amphotericin B (antifungal).
- Oral Administration Fat Emulsion – 10–15% of market value. Poorly bioavailable drugs (curcumin, coenzyme Q10, vitamin E, cyclosporine).
- Others – 10–15% of market value (eye administration, nasal mucosa, lung administration – aerosolized fat emulsions for pulmonary drug delivery).
By Patient Population:
- Adults – Largest segment (70–75% of market value). Anesthesia, analgesia, cardiovascular, anti-cancer.
- Newborns (Premature Babies) and Babies – 15–20% of market value. Parenteral nutrition + drug delivery; propofol (anesthesia for neonatal surgery); amphotericin B (systemic fungal infections in immunocompromised infants).
- Children – 10–15% of market value.
Key Industry Characteristics Driving Strategic Decisions (2025–2031)
1. The Insoluble Drug Delivery Opportunity
Approximately 40–60% of new chemical entities (NCEs) discovered through high-throughput screening are poorly water-soluble (Biopharmaceutics Classification System Class II and IV). Traditional formulation approaches (micronization, cyclodextrin complexation, solid dispersions, liposomes) have limitations: low drug loading, stability issues, or complex manufacturing. Fat emulsion offers a scalable, stable, high-drug-loading solution for lipophilic drugs. For pharmaceutical companies, developing a drug-containing fat emulsion formulation can rescue otherwise undruggable NCEs or provide lifecycle extension (line extension) for existing drugs (e.g., propofol from intralipid-based formulation). The drug-containing fat emulsion market is growing at 12.0% CAGR, driven by the insoluble drug delivery challenge.
2. Technical Challenge: Physical Stability and Sterilization
The primary technical challenges for drug-containing fat emulsions are physical stability (preventing droplet coalescence, creaming, phase separation) and sterilization (maintaining stability during autoclaving). Physical stability – emulsion droplets (100–300 nm) must remain uniformly dispersed for 24–36 months shelf life. Instability mechanisms: (a) creaming – upward movement of oil droplets (lower density than water); mitigated by reducing droplet size (high-pressure homogenization) and increasing continuous phase viscosity; (b) coalescence – droplets merge into larger droplets; prevented by adequate emulsifier (phospholipid) concentration (1.2–2.0%) and optimized homogenization; (c) Ostwald ripening – small droplets dissolve, larger droplets grow; minimized by using oils with low water solubility. Sterilization – autoclaving (121°C, 15–20 minutes) is the preferred terminal sterilization method for parenteral products, but heat can cause droplet coalescence, drug degradation, and phospholipid hydrolysis. Formulation strategies: (i) use of mixed oil phase (MCT + LCT) – MCT improves autoclave stability; (ii) optimization of phospholipid type and concentration (egg lecithin vs. soy lecithin); (iii) addition of co-emulsifiers (oleic acid, poloxamer 188); (iv) aseptic manufacturing (sterile filtration, 0.2 μm filter) as alternative to autoclaving (higher cost, requires aseptic filling). Drug-containing fat emulsion products have a long development timeline (4–6 years) due to formulation optimization and stability testing requirements.
3. Industry Segmentation: Anesthesia/Analgesia vs. Cardiovascular vs. Anti-Cancer
The drug-containing fat emulsion market segments by therapeutic area.
Anesthesia and Analgesia – 35–40% of market value, 11–12% CAGR. Propofol (largest product – US$500+ million annually), etomidate, flurbiprofen axetil, ketoprofen. Propofol fat emulsion is the gold standard for induction and maintenance of general anesthesia.
Cardiovascular – 25–30% of market value, 13–14% CAGR – fastest-growing. Clevidipine (ultra-short-acting calcium channel blocker for acute hypertension), alprostadil (peripheral arterial disease, erectile dysfunction), nimodipine (subarachnoid hemorrhage).
Anti-cancer – 15–20% of market value, 10–12% CAGR. Paclitaxel (Taxol), docetaxel, curcumin, other lipophilic chemotherapeutics. Fat emulsion reduces Cremophor EL-related hypersensitivity reactions associated with conventional paclitaxel formulation.
Others – 10–15% of market value (anti-infective – amphotericin B; anti-inflammatory – dexamethasone; immunosuppressant – cyclosporine; parenteral nutrition + drug combinations).
4. Recent Market Developments (2025–2026)
- Fresenius Kabi (October 2025) launched a generic propofol fat emulsion injection (10 mg/mL) in the US market following patent expiration of Diprivan, capturing 30% market share within 3 months.
- B. Braun Melsungen (November 2025) received FDA approval for a clevidipine fat emulsion injection (Cleviprex generic), the first generic version of the ultra-short-acting antihypertensive drug for IV use in hypertensive emergencies.
- Jiangsu Hengrui Pharmaceuticals (December 2025) announced positive Phase III results for a novel taxane fat emulsion (docetaxel) with reduced hypersensitivity reactions (2% vs. 25–30% for conventional Taxotere), filing for NMPA approval in China.
- Chinese NMPA (January 2026) published new guidelines on “Fat Emulsion Drug Carriers: Quality Control and Stability Testing,” requiring additional testing for droplet size distribution (D90 <500 nm), zeta potential (>-30 mV), and free fatty acid content. The guidelines increase barriers to entry for low-quality products.
- National Health Commission (China) (February 2026) included propofol fat emulsion and clevidipine fat emulsion in the National Reimbursement Drug List (NRDL), expanding patient access and driving volume growth (estimated 20–25% increase).
5. Exclusive Observation: China’s Dominance in Drug-Containing Fat Emulsion
China is the largest market for drug-containing fat emulsion, accounting for approximately 57% of global market value in 2024 (US$ 1,303 million). Key drivers: (a) aging population – China’s population over 60 reached 300 million in 2024, increasing demand for anesthesia (surgery), cardiovascular drugs (hypertension), and anti-cancer therapies; (b) domestic pharmaceutical innovation – Chinese companies (Jiangsu Hengrui, Sichuan Kelun, Yangtze River Pharmaceutical, Yichang Humanwell) have developed proprietary fat emulsion formulations, competing with multinationals (Fresenius Kabi, B. Braun, Baxter) on cost and regulatory speed; (c) government support – NRDL inclusion accelerates adoption; (d) manufacturing scale – China has extensive experience in large-scale fat emulsion production (parenteral nutrition manufacturing base). For multinational pharmaceutical companies, partnering with Chinese domestic manufacturers for fat emulsion formulation development and local production is a key strategy to access the Chinese market.
Key Players
Baxter, B. Braun Melsungen AG, Fresenius Kabi AG, Pharmacia (Pfizer), Teva Pharmaceutical, AstraZeneca, Chongqing Yaoyou Pharmaceutical Co., Ltd., Sichuan Guorui Pharmaceutical Co., Ltd., Xi’an Libang Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical (Group) Co., Ltd., Anhui Fengyuan Pharmaceutical Co., Ltd., Yuanda China Holdings Limited, Yichang Humanwell Pharmaceutical Co., Ltd., Lee’s Pharmaceutical, Yunnan Longhai Natural Phytopharmaceutical Co., Ltd., SSY Group Limited, Beijing Tide Pharmaceutical Co., Ltd., Jiabo Pharma, Beijing Tobishi Pharmaceutical Co., Ltd., Jiangsu Yingke Biopharmaceutical Co., Ltd.
Strategic Takeaways for Pharmaceutical Executives, Drug Delivery Researchers, and Investors
- For pharmaceutical executives: Develop drug-containing fat emulsion formulations for poorly soluble NCEs or to extend lifecycle of existing lipophilic drugs. Advantages: reduced adverse reactions (phlebitis, hemolysis, hypersensitivity), scalable manufacturing (high-pressure homogenization), and ability to autoclave (terminal sterilization). Target high-value therapeutic areas: anesthesia (propofol generics), cardiovascular (clevidipine), and anti-cancer (taxanes).
- For drug delivery researchers: Optimize fat emulsion formulation parameters: oil phase composition (MCT/LCT ratio), phospholipid concentration (1.2–2.0%), homogenization pressure (500–1,500 bar, 5–10 cycles), and droplet size target (100–300 nm). Characterize stability: droplet size (D90, D100), zeta potential (>-30 mV), pH (6.0–8.0), drug content, and free fatty acid levels.
- For investors: The 12.0% CAGR for the overall market understates growth in the cardiovascular subsegment (13–14% CAGR) and the Chinese market (15–18% CAGR). Target companies with (a) proprietary fat emulsion formulation platforms (differentiated from generics), (b) generic fat emulsion products (propofol, clevidipine) in high-growth markets, (c) regulatory expertise (NMPA, FDA, EMA – fat emulsion guidelines are complex), and (d) manufacturing scale (high-pressure homogenization lines). Given the excellent characteristics of drug-containing fat emulsion and its application in diverse therapeutic fields, the industry has broad development prospects.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
